Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preliminary observations using HIV-specific transfer factor in AIDS

G Pizza1, F Chiodo, V Colangeli

  • 1Immunodiagnosis and Immunotherapy Unit, Ospedale S. Orsola-Malpighi, Bologna, Italy.

Biotherapy (Dordrecht, Netherlands)
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transfer Factor as an Option for Managing the COVID-19 Pandemic.

Folia biologica·2020
Same author

The safety of available treatments options for neuroendocrine tumors.

Expert opinion on drug safety·2017
Same author

The treatment of hyperinsulinemic hypoglycaemia in adults: an update.

Journal of endocrinological investigation·2016
Same author

Hodgkin's Disease in 50 Intravenous Drug Users with HIV-Infection.

Leukemia & lymphoma·2016
Same author

Ruolo degli antisettici nel controllo delle infezioni nosocomiali.

Journal of chemotherapy (Florence, Italy)·2016
Same author

The international register of potentially toxic chemicals : Challenges of data collection in the field of toxicology.

Environmental science and pollution research international·2013
Same journal

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Elevated serum level of thioredoxin in patients with hepatocellular carcinoma.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Contribution of cytokines on the suppression of lung metastasis.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Levamisole and interleukin-2 for advanced malignancy.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.

Biotherapy (Dordrecht, Netherlands)·1999
See all related articles

Oral HIV-specific transfer factor (TF) shows promise for AIDS patients. This treatment, combined with antivirals, appears safe and aids in restoring immune response and clinical stability.

Area of Science:

  • Immunology
  • Virology
  • Clinical Medicine

Background:

  • Human Immunodeficiency Virus type 1 (HIV-1) infection affects the immune system, leading to Acquired Immunodeficiency Syndrome (AIDS).
  • Current treatments involve antiviral therapies, but immune restoration remains a challenge.

Purpose of the Study:

  • To evaluate the safety and potential efficacy of oral HIV-1-specific transfer factor (TF) in HIV-1-infected patients.
  • To assess the impact of TF on immune cell subsets and clinical status when used alongside antiviral treatments.

Main Methods:

  • Twenty-five HIV-1-infected patients (CDC stages II, III, IV) received oral TF with antiviral therapy for 60 to 1870 days.
  • Monitoring included lymphocyte counts, CD4 and CD8 subsets, and clinical assessment.
  • Delayed type hypersensitivity (DTH) responses to recall antigens were tested in anergic patients.

Related Experiment Videos

Main Results:

  • No statistically significant changes in lymphocyte or CD4/CD8 subsets were observed, though individual variations occurred.
  • Clinical improvement or stabilization was noted in 20 out of 25 patients.
  • Daily TF administration restored DTH responses in 12 out of 14 anergic patients within 60 days.

Conclusions:

  • Oral HIV-specific TF is well-tolerated in combination with antiviral drugs.
  • Preliminary data suggest potential clinical benefits and immune restoration in AIDS patients, warranting further research.